181 related articles for article (PubMed ID: 8329700)
1. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
3. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
4. [Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Hehlmann R; Heimpel H; Heinze B; Georgii A; Kolb HJ; Hossfeld DK; von Wussow P; Hochhaus A; Griesshammer M; Diehl V
Onkologie; 1991 Feb; 14(1):66-73. PubMed ID: 2057176
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
Hehlmann R; Heimpel H; Griesshammer M; Kolb HJ; Heinze B; Hossfeld DK; Wickramanayake PD; Essers U; Thiele J; Georgii A
Leukemia; 1992; 6 Suppl 3():110S-114S. PubMed ID: 1602805
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944
[TBL] [Abstract][Full Text] [Related]
7. Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival.
Hehlmann R; Heimpel H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():161-7. PubMed ID: 8951787
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
[TBL] [Abstract][Full Text] [Related]
9. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
Goldman JM; Szydlo R; Horowitz MM; Gale RP; Ash RC; Atkinson K; Dicke KA; Gluckman E; Herzig RH; Marmont A
Blood; 1993 Oct; 82(7):2235-8. PubMed ID: 8400272
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897].
Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
Onkologie; 1988 Feb; 11(1):25-9. PubMed ID: 3283622
[TBL] [Abstract][Full Text] [Related]
11. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
[TBL] [Abstract][Full Text] [Related]
12. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
[TBL] [Abstract][Full Text] [Related]
13. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival.
Olsson-Strömberg U; Simonsson B; Ahlgren T; Björkholm M; Carlsson K; Gahrton G; Hast R; Löfvenberg E; Linder O; Ljungman P; Malm C; Paul C; Rödjer S; Turesson I; Udén AM; Wahlin A; Killander A; Wadman B; Westin J; Vikrot O; Zettervall O; Oberg G;
Hematol J; 2004; 5(6):462-6. PubMed ID: 15570285
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
15. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Buesche G; Hehlmann R; Hecker H; Heimpel H; Heinze B; Schmeil A; Pfirrmann M; Gomez G; Tobler A; Herrmann H; Kappler M; Hasford J; Buhr T; Kreipe HH; Georgii A
Leukemia; 2003 Dec; 17(12):2444-53. PubMed ID: 14562117
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.
Rushing D; Goldman A; Gibbs G; Howe R; Kennedy BJ
Am J Clin Oncol; 1982 Jun; 5(3):307-13. PubMed ID: 6952759
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group.
Br J Haematol; 2000 Sep; 110(3):573-6. PubMed ID: 10997966
[TBL] [Abstract][Full Text] [Related]
18. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Berger U; Maywald O; Pfirrmann M; Lahaye T; Hochhaus A; Reiter A; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2005 Jun; 19(6):984-9. PubMed ID: 15830009
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelogenous leukemia: a review.
Cortes JE; Talpaz M; Kantarjian H
Am J Med; 1996 May; 100(5):555-70. PubMed ID: 8644769
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.
Hehlmann R; Kister P; Willer A; Simon M; Schenk M; Seifarth W; Papakonstantinou G; Saussele S; Kolb HJ; Ansari H
Leukemia; 1994 Apr; 8 Suppl 1():S127-32. PubMed ID: 8152279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
